0

Xstrahl In Action: SARRP Used for Research into Craniospinal Irradiation for Very-High-Risk Medulloblastoma

Craniospinal irradiation (CSI) is a crucial component of treatment for medulloblastoma (MB), a brain tumor clinically stratified into prognostically distinct molecular subgroups. Preclinical [...]

0

Xstrahl Supporting Norfolk & Norwich Skin Cancer Radiotherapy Study Day

Nearly 50 trainee oncology doctors attended a skin cancer radiotherapy study day at Norfolk & Norwich Hospital (UK) on Saturday, supported by sponsorship from Xstrahl. The annual event, which [...]

0

SARRP customer presentations at AAPM 2019

With the 61st annual American Association of Physicists in Medicine ending, the cutting-edge preclinical research created with Xstrahl systems has once again been a main feature of the event. [...]

0

Xstrahl In Action: Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism

Tumor hypoxia reduces the effectiveness of radiation therapy by limiting the biologically effective dose. An acute increase in tumor oxygenation before radiation treatment should therefore [...]

0

Xstrahl In Action: Orally Bioavailable ATM Inhibitor Radiosensitizes Intracranial Gliomas

Inhibition of ataxia-telangiectasia mutated (ATM) during radiotherapy of glioblastoma multiforme (GBM) may improve tumor control by short-circuiting the response to radiation-induced DNA damage. [...]

0

Xstrahl In Action: Behavioral Effects of Focal Irradiation in a Juvenile Murine Model

Chemotherapy has been successfully used to reduce radiation dose and volume for most paediatric patients. However, because of the failure of chemotherapeutic agents to cross the blood-brain [...]